202
Views
4
CrossRef citations to date
0
Altmetric
Original Research

Prevalence of Patients with Uncontrolled Asthma Despite NVL/GINA Step 4/5 Treatment in Germany

, , , , , , , , & ORCID Icon show all
Pages 897-906 | Published online: 04 Jul 2022

References

  • Virchow JC. Asthma - historical development, current status and perspectives. Pneumologie. 2010;64(9):541–549. doi:10.1055/s-0030-1255695
  • Papaioannou AI, Kostikas K, Zervas E, Kolilekas L, Papiris S, Gaga M. Control of asthma in real life: still a valuable goal?. Eur Respir Rev. 2015;24(136):361–369. doi:10.1183/16000617.00001615
  • Reddel HK, Boulet LP; Global Initiative for Asthma. Global strategy for asthma management and prevention; 2021. Available from: www.ginasthma.org. Accessed June 13, 2022
  • Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343–373. doi:10.1183/09031936.00202013
  • Pepper AN, Renz H, Casale TB, Garn H. Biologic therapy and novel molecular targets of severe asthma. J Allergy Clin Immunol Pract. 2017;5(4):909–916. doi:10.1016/j.jaip.2017.04.038
  • Summary of product characteristics benralizumab. Available from: https://wwwemaeuropaeu. Accessed June 13, 2022
  • Del Giacco SR, Bakirtas A, Bel E, et al. Allergy in severe asthma. Allergy. 2017;72:207–220. doi:10.1111/all.13072
  • Kaur R, Chupp G. Phenotypes and endotypes of adult asthma: moving toward precision medicine. J Allergy Clin Immunol. 2019;144:1–12. doi:10.1016/j.jaci.2019.05.031
  • Taube C, Bramlage P, Hofer A, Anderson D. Prevalence of oral corticosteroid use in the German severe asthma population. ERJ Open Res. 2019;5(4):00092–2019. doi:10.1183/23120541.00092-2019
  • Rathmann W, Bongaerts B, Carius H, Kruppert Y, Kostev K. Basic characteristics and representativeness of the German Disease Analyzer database. Int J Clin Pharmacol Ther. 2018;56:459–466. doi:10.5414/CP203320
  • Steppuhn H, Kuhnert R, Scheidt-Nave C. 12-Monats-Prävalenz von Asthma bronchiale bei Erwachsenen in Deutschland. J Health Monit. 2017;2(3). doi:10.17886/RKI-GBE-2017-052
  • Worth H, Criée CP, Vogelmeier CF, et al. Prevalence of overuse of short-acting beta-2 agonists (SABA) and associated factors among patients with asthma in Germany. Respir Res. 2021;22(1). doi:10.1186/s12931-021-01701-3
  • Janson C, Menzies‑Gow A, Nan C, Nuevo J, Papi A, Quint J. SABINA: an overview of short‑acting β2‑agonist use in asthma in European countries. Adv Ther. 2020;37:1124–1135. doi:10.1007/s12325-020-01233-0
  • Lommatzsch M, Wilmer C, Sauerbeck IS. Prevalence of the use of oral corticosteroids in asthma-a 3-year analysis in Germany. Eur Respir J. 2019;54:00092–2019
  • Hekking PPW, Wener RR, Amelink M, Zwinderman AH, Bouvy ML, Bel EH. The prevalence of severe refractory asthma. J Allergy Clin Immunol. 2015;135(4):896–902. doi:10.1016/j.jaci.2014.08.042